Investigating the Novel Observation of Right-Left Difference in Uterine Artery Vascular Resistance in Pre-Eclampsia

The recruitment status of this study is unknown because the information has not been verified recently.

Verified February 2009 by Hadassah Medical Organization.
Recruitment status was Not yet recruiting

Sponsor:

Information provided by:

Hadassah Medical Organization

ClinicalTrials.gov Identifier:

NCT00848679

First received: February 19, 2009

Last updated: NA

Last verified: February 2009

History: No changes posted

Purpose

The investigators previously demonstrated that epidural ropivacaine reduces uterine artery vascular resistance in a dose dependent manner in pre-eclampsia. The investigators also noted a marked right-left difference in vascular resistance between paired uterine arteries, which was almost completely abolished following epidural ropivacaine. However, this novel observation was not a stated outcome variable before the study began. This study assesses right-left difference in vascular resistance between paired uterine arteries as a primary end-point, assesses the dose-response effect of epidural lidocaine and compares the effect observed in pre-eclampsia with that in two control populations (term normal pregnancy and non-pregnant controls).

Condition	Intervention	Phase
Pre-Eclampsia	Drug: Epidural lidocaine Drug: Epidural lidocaine 2%	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Investigating the Novel Observation of Right-Left Difference in Uterine Artery Vascular Resistance in Pre-Eclampsia: A Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Dose-Dependent Effect of Epidural Lidocaine on Right-Left Uterine Artery Blood Flow Differences in Pre-Eclampsia, With Healthy Term Pregnant and Non-Pregnant Controls

Resource links provided by NLM:

Genetics Home Reference related topics: preeclampsia

Drug Information available for: Lidocaine hydrochloride Lidocaine

Genetic and Rare Diseases Information Center resources: Eclampsia

U.S. FDA Resources

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:

Uterine artery pulsatility index (by Doppler ultrasound). Specifically the right-left uterine artery difference. [ Time Frame: 15min after each dose - on a dose--response curve ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Uterine artery pulsatility index (worse vessel) [ Time Frame: 15 min after dose ] [ Designated as safety issue: No ]


Estimated Enrollment:	60
Study Start Date:	March 2009
Estimated Study Completion Date:	October 2009
Estimated Primary Completion Date:	October 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Epidural lidocaine 30 women to receive 5 x 5mL boluses of epidural lidocaine 2%. 10 pre-eclampsia, 10 term pregnancy, 10 non-pregnant.	Drug: Epidural lidocaine Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect. Drug: Epidural lidocaine 2% 5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
Placebo Comparator: Epidural saline 30 women to receive 5 x 5 mL boluses of epidural saline. 10 pre-eclamptics, 10 normal term pregnancy, 10 non-pregnant	Drug: Epidural lidocaine Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect. Drug: Epidural lidocaine 2% 5 x 5ml boluses of either epidural lidocaine 2% or epidural saline

Eligibility


Ages Eligible for Study:	18 Years to 40 Years (Adult)
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Pre-eclampsia patients and normal pregnancy controls scheduled to receive epidural catheterization for induction of labor or Cesarean delivery. Non-pregnant controls receiving epidural catheterization for elective surgery. Pre-eclampsia group:
1. gestational age between 35 to 40 completed weeks
2. uterine artery notching OR evidence of reduced uterine artery blood flow
3. resting systolic pressure > 140mmHg or diastolic pressure > 90mmHg measured twice at least 6 hours apart
4. proteinuria (at least 0•1 g/l in two random samples at least 6 hours apart or at least 0•3g in a 24 hour collection).
Normal pregnancy control group:
1. gestational age between 35 to 40 completed weeks
2. absence of other inclusion factors for the pre-eclampsia group. Non-pregnant control group: Non-pregnant women of reproductive age.

Exclusion Criteria:

Active labor, resting blood pressure ≥ 160/110 (recorded on at least two occasions 6 hours apart), coagulopathy or other contraindications for epidural catheterization, abnormal fetal heart tracing, known fetal anomaly, intrauterine infection, placental anomalies, twins, and refusal of consent.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00848679

Contacts


Contact: Yehuda Ginosar, BSc MBBS	+972-507-874388	yginosar@netvision.net.il
Contact: Uriel Elchalal, MD	+972-507-874356	uriele@ekmd.huji.ac.il

Locations


Israel
Hadassah Hebrew University Medical Center	Not yet recruiting
Jerusalem, Israel, 91120
Contact: Yehuda Ginosar, BSc MBBS +972-507-874388 yginosar@netvision.net.il
Contact: Uriel Elchalal, MD +972-507-874356 uriele@ekmd.huji.ac.il
Principal Investigator: Yehuda Ginosar, BSc MBBS
Sub-Investigator: Uriel Elchalal, MD
Sub-Investigator: Michel Nadjari, MD

Sponsors and Collaborators

Hadassah Medical Organization

More Information

Publications:

Ginosar Y, Nadjari M, Hoffman A, Firman N, Davidson EM, Weiniger CF, Rosen L, Weissman C, Elchalal U; ACET study group. Antepartum continuous epidural ropivacaine therapy reduces uterine artery vascular resistance in pre-eclampsia: a randomized, dose-ranging, placebo-controlled study. Br J Anaesth. 2009 Mar;102(3):369-78. doi: 10.1093/bja/aen402. Epub 2009 Jan 27.


Responsible Party:	Dr Yehuda Ginosar, Hadassah Medical Organization
ClinicalTrials.gov Identifier:	NCT00848679 History of Changes
Other Study ID Numbers:	ACET3-ginosar-HMO-CTIL
Study First Received:	February 19, 2009
Last Updated:	February 19, 2009
Health Authority:	Israel: Ministry of Health

Keywords provided by Hadassah Medical Organization:


Pre-eclampsia Pregnancy Uteroplacental blood flow Epidural Anesthesia

Additional relevant MeSH terms:


Eclampsia Pre-Eclampsia Hypertension, Pregnancy-Induced Pregnancy Complications Lidocaine Anesthetics, Local Anesthetics Central Nervous System Depressants	Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Anti-Arrhythmia Agents Voltage-Gated Sodium Channel Blockers Sodium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 27, 2016

To Top